AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04469296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein restricted diet
Description: A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.
Study NCT05372523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5 Assessment
Description: A validated, semi-structured clinical interview to assess core PTSD symptoms
Study NCT05372523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye OBCI
Description: Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
Study NCT06495086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: The NIV group received bilevel-positive airway pressure. During NIV, the tidal volume was set to 6-8 mL/kg, positive expiratory end pressure (PEEP) to 3-5 cm H2O, and pressure support ventilation (PSV) to 8-12 cm H2O by a clinician with 8 years of experience. To reduce potential bias, the clinician was blinded to the null hypothesis.
Study NCT06495086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC-30
Description: The HFNC-30 group received HFNC therapy at flow rates of 30 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
Study NCT06495086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC-50
Description: The HFNC-50 group received HFNC therapy at flow rates of 50 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
Study NCT05535348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for Father of CYSHCN
Description: Virtually delivered psycho-educational resiliency training program for fathers of CYSHCN
Study NCT05632185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Equine-assisted Therapy
Description: An equine therapy session typically consists of specific tasks and challenges to overcome, with the aid and guidance of horses. There is no riding involved and no specific skills are necessary to take part in these sessions
Study NCT04774835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIVST
Description: aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV self-testing by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
Study NCT04774835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard aPS
Description: aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV testing at their local HTS location by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
Study NCT06355778 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer Tasks
Description: Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
Study NCT05667714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA58 Nasal Spray
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Study NCT05667714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided by Sinovac Life Sciences Co. , Ltd.
Study NCT05070221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
Description: less than 8mL/time，Q2W，i.t.；
Study NCT05070221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody for injection
Description: 200mg/time，Q3W，i.v.；
Study NCT05070221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg，bid，p.o.；
Study NCT05656924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital prosthetic interface technology
Description: Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
Study NCT05564065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency thermocoagulation of sensory branches of hip joint
Description: There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
Study NCT05564065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular steroid injection of hip joint
Description: Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
Study NCT05913414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Patients receive Iron isomaltoside after IC and CCRT
Study NCT05913414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polysaccharide Iron Complex Pill
Description: Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
Study NCT05913414 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received intensity-modulated radiotherapy before enrolled.
Study NCT05913414 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: All patients received intensity-modulated radiotherapy before enrolled.
Study NCT06437678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Irinotecan Hydrochloride
Description: Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks
Study NCT06020456 — intervention group
Intervention type: DRUG
Intervention: Desmopressin
Description: For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
Study NCT05985031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tendon tap
Description: While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.
Study NCT05985031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tendon tap
Description: While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.
Study NCT05985031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tibial nerve stimulation
Description: H-reflex responses were examined by tibial nerve stimulation
Study NCT05985031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tibial nerve stimulation
Description: H-reflex responses were examined by tibial nerve stimulation
Study NCT05026307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of pterygium
Description: Simple surgical excision of pterygium with bare sclera
Study NCT05395065 — intervention group
Intervention type: DEVICE
Intervention: Silver Diamine Fluoride/Sodium Fluoride Varnish
Description: Application of dental caries arresting topical medication
Study NCT04742088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ankleSOFT100
Description: During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
Study NCT05138081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching
Description: Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion.
Study NCT05138081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization
Description: Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
Study NCT06475014 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee replacement
Description: Mechanical Alignment Using PSI Pre and post-operative CT Scan
Study NCT06131879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Biostimulation of temporalis and masseter muscles
Study NCT06131879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified physical therapy
Description: Progressive muscle relaxation of temporalis and masseter muscles
Study NCT05292105 — intervention group
Intervention type: DEVICE
Intervention: NC Xperience
Description: Coronary dilatation balloon catheter (non compliant)
Study NCT05965284 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azathioprine
Description: All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
Study NCT05965284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
Study NCT05965284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
Study NCT06437808 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Training with Portable Force Plates Integration
Description: This group will undergo football training sessions that incorporate the use of portable force plates. These devices will measure ground reaction forces and provide real-time data on players' movements, balance, and pressure points. The data collected will be used to create personalized training programs aimed at optimizing performance and reducing the risk of injuries.
Study NCT06437808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Training
Description: This group will continue with the existing football training regimen without the use of portable force plates. Training will follow the traditional methods used at the Multan Sports Complex, focusing on physical conditioning, technical skills, and tactical awareness without the advanced biomechanical analysis provided by the force plates.
Study NCT05875259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
Study NCT05875259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Study NCT05875259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1 + BR1019-2
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support
Description: Receive $1000 preloaded cash card
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support
Description: Receive $100 preloaded cash card
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06771739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06771180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-CyBorD
Description: Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.
Study NCT06190171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active respiratory muscle strength training
Description: Devices will be set to 60% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).
Study NCT06190171 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham respiratory muscle strength training
Description: Springs will be removed from devices to ensure training is done without resistance. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory sham muscle strength training (a total of 50 repetitions).
Study NCT06409676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocols
Description: Enhanced Recovery After Surgery (ERAS) guidelines are evidence-based recommendations aimed at improving patient outcomes and reducing complications after surgery.
Study NCT01437020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH708980 Anti-IL-10 monoclonal
Description: Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
Study NCT01437020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
Study NCT04394533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine (Hyperbaric 2%)
Description: 2 ml hyperbaric prilocaine
Study NCT04394533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Hyperbaric 0.5%)
Description: 2 ml hyperbaric bupivacaine
Study NCT06770179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recruitment maneuver
Description: in the group 2, in addition to the fixed PEEP of 5 cm H₂O, a recruitment maneuver is planned at the end of the surgery. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, before extubation.
Study NCT04683965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 d1
Study NCT04683965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12
Study NCT04683965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg d1,d14
Study NCT06417021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Frontal Ultrasound Machine
Description: Ultrasound machine will be placed in a frontal position
Study NCT06417021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lateral Ultrasound Machine
Description: Ultrasound machine will be placed in a lateral position
Study NCT04670640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.
Study NCT04670640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Focus
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.
Study NCT04670640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Distractions
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
Study NCT05607875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Grow to Recovery Train-the-Trainer program
Description: Mental health professionals will receive an online training, a trainer manual, a recovery manual (for people with mental illness), and Pathways to Recovery: A Strengths Recovery Self-help Workbook. The online training includes the concept of recovery, the implementation of recovery-oriented services, and the introduction of the Grow to recovery group. After the training, these professionals will conduct a 5-month Grow to recovery group in their own organization.~People with mental illness will attend the Grow to recovery group delivered by mental health professionals who has received the online training.
Study NCT05607875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Mental health professionals will not receive any training. People with mental illness will receive a spiritual book and read by themselves.
Study NCT04697628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: 2.0 mg/kg every 3 weeks (Q3W)
Study NCT04697628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan
Description: 1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
Study NCT04697628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: 30 mg/m2 IV on Days 1 and 8, every 21 days
Study NCT04697628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 mg/m2 IV on Days 1 and 8, every 21 days
Study NCT04697628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 100 or 125 mg/m2 IV weekly for 28 days, every 42 days
Study NCT04697628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/m2 IV on Day 1, every 21 days
Study NCT05670587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
Description: A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.